In an effort to simplify the table appearing as part of Figure 1 in the “Update on the Canadian Diabetes Association 2008 clinical practice guidelines,”1 an error was inadvertently introduced. The row on sulfonylureas should have included metiglinides; the comments about improved postprandial control and 3 to 4 daily doses only apply to metiglinides. Metiglinides improve postprandial control and require 3 to 4 daily doses, while sulfonylureas are associated with weight gain. The authors apologize for this error and any confusion it might have caused.
- Copyright© the College of Family Physicians of Canada